Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS–MAPK pathway and TP53 as potential predictors of immunotherapy efficacy-Reference-Cited by-同舟云学术

Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS–MAPK pathway and TP53 as potential predictors of immunotherapy efficacy

Published:2021-07 Issue:7 Volume:32 Page:906-916
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Wang J.Y.,Xiu J.,Baca Y.,Arai H.,Battaglin F.,Kawanishi N.,Soni S.,Zhang W.,Millstein J.,Shields A.F.,Grothey A.,Weinberg B.A.,Marshall J.L.,Lou E.,Khushman M.,Sohal D.P.S.,Hall M.J.,Oberley M.,Spetzler D.,Shen L.,Korn W.M.,Lenz H.J.

Funder

NCI

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference46 articles.

1. FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1;Fashoyin Aje;Oncologist,2018

2. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer;Kojima;J Clin Oncol,2020

3. Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1–positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies;Wainberg;J Clin Oncol,2020

4. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial;Shitara;JAMA Oncol,2020

5. Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): first results of the CheckMate 649 study;Moehler;Ann Oncol,2020

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MDM2 inhibitors in cancer immunotherapy: Current status and perspective;Genes & Diseases;2024-11

2. The Landscape and Prognosis of Microsatellite Stable (MSS) Esophageal, Gastro-Esophageal Junction and Gastric Adenocarcinomas with High Tumor Mutation Burden (TMB);Cancer Investigation;2024-08-08

3. New clinical trial design in precision medicine: discovery, development and direction;Signal Transduction and Targeted Therapy;2024-03-04

4. Molecular subtypes of disulfidptosis-regulated genes and prognosis models for predicting prognosis, tumor microenvironment infiltration, and therapeutic response in hepatocellular carcinoma;International Journal of Biological Macromolecules;2024-03

5. Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies;Drugs;2023-12-18